本帖最后由 老马 于 2012-1-13 21:20 编辑
4 ?4 o" N u& N+ x
9 f/ q. ^& D# t5 W% @( }% `5 d+ R" f爱必妥和阿瓦斯丁的比较
4 f( ]4 m" D+ G* J
- {5 D: t% x4 F2 t) Z
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/3 U F9 r8 y5 ~) ^5 y) ^
8 J, B A O+ y0 F9 ]
& F! H! t K/ `/ Z$ h h) |
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
$ l0 @& v$ J( t0 d' u==================================================
: p. n! C; d( v9 O0 qOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
8 ?) o- z: T5 b' j7 d. h) QPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
+ v+ P1 {0 [% RResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
" W2 G/ X& \# ]$ H$ u) ~
|